Here, we determined in how far BTK inhibition by Ibrutinib is affecting MALT1 activity in ABC DLBCL cells that carry oncogenic mutations in either CD79 or CARMA1. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.